Getting to Know Pfizer’s New Chief Medical Officer Aida Habtezion
The Facts About Pfizer and BioNTech’s COVID-19 Vaccine
COVID-19 SCIENTIFIC RESOURCES
Global Survey Results: Cancer & Aging
Find a Trial
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
THE ANTIGEN: #COVID19 PODCAST
VISIT OUR COVID-19 HUB
Latest News
Approval is based on CROWN trial, which showed a 72% reduction in risk of progression or death for treatment with LORBRENA vs. XALKORI® The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA ® (lorlatinib), expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). LORBRENA is now indicated for adults with metastatic NSCLC whose…